Relmada Therapeutics Stock Surges After Strong NDV-01 Bladder Cancer Data and $160 Million Raise

Relmada shares jumped sharply after positive 12-month Phase 2 trial data for NDV-01 in bladder cancer and announcement of $160M financing to advance development.